Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

4,195 5,566 8,964

Impairment of long-lived

asset held for sale 735 - 735 -

-------------------------------------------------------------------------

21,904 18,394 76,822 62,570

-------------------------------------------------------------------------

Loss from operations (11,664) (6,457) (34,754) (23,771)

-------------------------------------------------------------------------

Other revenues (expenses)

Interest income 535 703 1,904 1,441

Interest expense (23) 14 (85) (1,433)

Foreign exchange gain

(loss) (269) 384 (1,035) 319

Loss on disposal of

equipment (28) - (28) -

Gain on disposal of

long-term investment - 409 - 409

Other - (163) - -

-------------------------------------------------------------------------

215 1,347 756 736

-------------------------------------------------------------------------

Share in the results

of an affiliated

company - 1,575 - 1,575

-------------------------------------------------------------------------

Loss before Income taxes (11,449) (3,535) (33,998) (21,460)

Income tax recovery

(expense) (2,405) 26,061 1,961 29,037

-------------------------------------------------------------------------

Net earnings (loss) from

continuing operations (13,854) 22,526 (32,037) 7,577

Net earnings (loss) from

discont
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 The Collaborative R&D Terms ... provides comprehensive understanding and unprecedented access to the ... the worlds leading life science companies. , The ... how and why companies enter collaborative R&D deals. ... negotiated deals terms provides critical insight into the ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
(Date:8/31/2014)... August 31, 2014 This is ... state of the Epoxy Hardener industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... MELVILLE, N.Y., July 31 Gentiva Health,Services, ... provider of,comprehensive home health services, today reported strong ... revenues and admissions,in the Company,s Home Health segment., ... for the quarter ended June 29, 2008 included:, ...
... MD (creator of the Hydro-Pulse sinus irrigation device) describes ... anti-inflammatories directly into the sinus cavities using a pulsating ... his patients who experience symptoms of sinus infections, snoring ... ...
... Nektar,Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, August 6, 2008, after the,close of U.S.-based financial ... a conference call to review the results,beginning at 5:00 ... The press release and a live audio-only Webcast of ...
Cached Biology Technology:Gentiva Reports Strong Second Quarter led by Home Health Segment 2Gentiva Reports Strong Second Quarter led by Home Health Segment 3Gentiva Reports Strong Second Quarter led by Home Health Segment 4Gentiva Reports Strong Second Quarter led by Home Health Segment 5Gentiva Reports Strong Second Quarter led by Home Health Segment 6Gentiva Reports Strong Second Quarter led by Home Health Segment 7Gentiva Reports Strong Second Quarter led by Home Health Segment 8Gentiva Reports Strong Second Quarter led by Home Health Segment 9Gentiva Reports Strong Second Quarter led by Home Health Segment 10Gentiva Reports Strong Second Quarter led by Home Health Segment 11Gentiva Reports Strong Second Quarter led by Home Health Segment 12Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets 2
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... in German . ... is considered the oldest form of communication. Acting as ... example, the sexual attraction between males and females. Fish ... coordinate reproductive behavior in males and females. Scientists at ... Algarve in Faro, Portugal, and at the Max Planck ...
(Date:8/29/2014)... Tibetan plateau -- the largest topographic anomaly above sea ... profound effect on climate and its reflection of continental ... , Katharine Huntington and colleagues employ a cutting-edge geochemical ... fossil snail shells to investigate the uplift history of ... range widely on the timing of surface uplift of ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... with Staphylococcus aureus bacteria, a leading cause of ... infections, including the antibiotic-resistant strain MRSA. University of ... the immense success of S. aureus the ability to ... to destroy white blood cells. The study was published Nov ...
... are more fattening than others? What about the risks ... for Nutrition (ASN) on December 5-7 for answers to ... in Clinical Nutrition Conference. The 3-day program ... several different satellite sessions, and networking opportunities. Credentialed media, ...
... Nov. 19, 2013   The Bensalem Township Police Department , ... in the field of DNA testing.  This pilot program known ... first of its kind in the country for law enforcement. ... local DNA database with over 6,000 DNA profiles consisting of ...
Cached Biology News:Staphylococcus aureus bacteria turns immune system against itself 2Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... Novagen's frozen Sf9 Insect Cells are derived from ... pretested for optimal growth, use in transfections, plaque ... are frozen in a protocol that optimizes recovery ... for growth in serum-free BacVector Insect Cell Medium ...
Biology Products: